



CooperVision's Dr. Arthur Bradley Recognized as a 2024 Wavefront Congress Luminary

Dr. Bradley Lauded for His Distinguished Career and Ongoing Contributions to Myopia Management and Optometry Mentorship

SAN RAMON, Calif., March 11, 2024—The [Wavefront Congress](#), a convergence of global experts and thought leaders in optical sciences and wavefront technologies for eye care, has recognized Arthur Bradley, Ph.D., Research Fellow at [CooperVision](#), as a 2024 Luminary for his outstanding contributions to the optometry field for over more than four decades.

The honor was awarded to him during the annual event, which drew over 100 optical scientists, clinicians, surgeons, corporate scientists from around the world to Houston. In addition to receiving his Luminary recognition, Dr. Bradley shared insights from his seven-year trial on the cumulative treatment effect and efficacy of MiSight® 1 day[†] contact lenses, presenting findings derived from the multi-year international clinical study. A prolific researcher, Dr. Bradley has authored nearly 200 scientific papers and over 200 abstracts to date.

Before joining CooperVision in 2019, Dr. Bradley built a celebrated career as a vision science professor and researcher at Indiana University. Throughout his tenure, he provided mentorship and guidance to the thousands of students he taught in various fields, including optics, visual neuroscience, binocular vision, and visual function.

“Dr. Bradley has made significant contributions to the field of optometry, especially in developing novel ways to examine the visual and ophthalmic systems,” said Francis Erard, CooperVision's Vice President of Research and Development. “For decades he has been a Luminary to thousands of young scientists, as well as optometrists, ophthalmologists, and research peers, encouraging a deeper understanding of human vision and optics.”

Dr. Bradley and the CooperVision Research and Development myopia team have garnered global recognition for groundbreaking research on optical interventions that are helping to address the myopia epidemic.* His significant contributions, particularly in the context of MiSight® 1 day, have propelled the fields of myopia control and myopia management forward. Dr. Bradley's work continues to receive widespread recognition and is regularly featured at major conferences. Last year, Dr. Bradley was [inducted](#) into the University of California Berkeley School of Optometry's Hall of Fame

“Guiding the next generation of research scientists is an essential aspect of the scientific journey,” said Dr. Bradley. “Whether in a university or corporate setting, I believe we have an innate mentorship responsibility. Hopefully, this recognition will help shine a brighter spotlight on opportunities to collaborate with emerging ocular scientists, building an even more promising future together.”

Dr. Bradley was named a 2024 Luminary along with Dr. Ray Applegate, Dr. Larry Thibos, and Dr. Jim Schwiegerling (posthumously).

For more information on CooperVision's myopia control and management advancements, visit www.coopervision.com.



* MiSight® 1 day clinical study is the longest continuous soft contact lens study for myopia management.

† **Canadian Indications for Use:** MiSight 1 day (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

#

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Media Contact

Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-434-2153